Glaucoma News and Research

Latest Glaucoma News and Research

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

27 Apr 2012

Checklist for seniors to reduce risk of falls

For those 65 and older, falling can be fatal; in fact, the Centers for Disease Control and Prevention (CDC) reports that falls are the leading cause of injury-related deaths among this age group, and some 40 percent of seniors fall at least once each year. Additionally, one in four who sustains a hip fracture from a fall will die within a year, and another 50 percent will never return to their pre-fall level of mobility.

27 Apr 2012

Caffeine increases eye's ability to produce tears

Researchers at the University of Tokyo's School of Medicine have shown for the first time that caffeine intake can significantly increase the eye's ability to produce tears, a finding that could improve treatment of dry eye syndrome. This common eye condition affects about four million people age 50 and older in the United States.

18 Apr 2012

Viewpoints: Santorum pushed Romney on health care; GOP's 'classic male mistake'; ACOs and the anti-trust challenge

The Pennsylvanian was also by far the most effective Republican critic of RomneyCare. When he stood on stage in a debate and took apart the Massachusetts health law as a prototype for ObamaCare, Mr. Romney realized he couldn't coast to the nomination. That's when the former Massachusetts Governor came out with his own tax cut and tax reform plan to appeal to economic conservatives.

12 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Stress-induced tolerance can prevent glaucoma

Working in mice, scientists at Washington University School of Medicine in St. Louis have devised a treatment that prevents the optic nerve injury that occurs in glaucoma, a neurodegenerative disease that is a leading cause of blindness.

4 Apr 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Canon to showcase RK-F2 Full Auto Ref-Keratometer at Vision Expo East

Canon U.S.A., Inc., a leader in digital imaging solutions, will demonstrate the benefits of using its digital imaging and workflow management solutions, including the Canon RK-F2 Full Auto Ref-Keratometer, during Vision Expo East, March 23 - 25, at the Jacob K. Javits Convention Center in New York.

23 Mar 2012

Single dose of X-ray radiation can prevent glaucoma

Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from glaucoma.

20 Mar 2012

DMEI chooses ifa EMR v6 as future Electronic Medical Record system

ifa united i-tech, a U.S. subsidiary of ifa Systems AG, the global leader for IT solutions in ophthalmology, announced that the Dean McGee Eye Institute (DMEI) selected ifa EMR v6 as its future Electronic Medical Record (EMR) system.

17 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The Hydrus Microstent is the world's first intracanalicular scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States.

6 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.’s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow’s treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.

1 Mar 2012